Beta-Amyloid Deposition in the Temporal Lobe of Patients with Dementia with Lewy Bodies: Comparison with Non-Demented Cases and Alzheimer’s Disease

2000 ◽  
Vol 11 (4) ◽  
pp. 187-192 ◽  
Author(s):  
R.A. Armstrong ◽  
N.J. Cairns ◽  
P.L. Lantos
2010 ◽  
Vol 21 (4) ◽  
pp. 1129-1140 ◽  
Author(s):  
Michael J. Firbank ◽  
Andrew M. Blamire ◽  
Andrew Teodorczuk ◽  
Emma Teper ◽  
Emma J. Burton ◽  
...  

1999 ◽  
Vol 29 (1) ◽  
pp. 181-187 ◽  
Author(s):  
G. T. HARVEY ◽  
J. HUGHES ◽  
I. G. McKEITH ◽  
R. BRIEL ◽  
C. BALLARD ◽  
...  

Background. Temporal lobe atrophy on magnetic resonance imaging (MRI) has been suggested as a specific diagnostic marker for Alzheimer's disease (AD). No previous comparison with dementia with Lewy bodies (DLB) has been reported.Method. T1-weighted MRI scans were performed on 11 subjects with AD (nine with NINCDS/ADRDA probable AD and two with neuropathologically proven AD) and nine subjects with DLB (four with probable DLB diagnosed by clinical criteria and five with neuropathologically proven DLB). Groups were matched for age, duration of illness and cognitive test score. Two raters, blind to diagnosis and neuropathological findings, measured the volumes of the frontal lobes, temporal lobes, hippocampi, parahippocampal gyri, amygdalae, and caudate nuclei using a computerized volumetric analysis system. Scans were also rated for medial temporal atrophy on a four-point scale by an experienced rater.Results. AD subjects had significantly smaller left temporal lobes and parahippocampal gyri than those with DLB. Medial temporal atrophy was present in 9/11 AD cases (82%) and absent in 6/9 (67%) of DLB cases. Two neuropathologically confirmed cases of DLB had severe medial temporal atrophy; both had concurrent AD-type pathology in the temporal lobe (Braak stage 4).Conclusions. This pilot study supports the hypothesis that a greater burden of pathology centres on the temporal lobes in AD compared with DLB, except in DLB cases with concurrent Alzheimer pathology. A larger study is needed to confirm these findings and to determine whether MRI has a role in assisting with the clinical differentiation between DLB and AD.


2012 ◽  
Vol 25 (1) ◽  
pp. 111-119 ◽  
Author(s):  
James O'Donovan ◽  
Rosie Watson ◽  
Sean J. Colloby ◽  
Michael J. Firbank ◽  
Emma J. Burton ◽  
...  

ABSTRACTBackground: Previous studies suggest that posterior cortical atrophy may be a useful marker for early onset Alzheimer's disease (AD). Dementia with Lewy bodies (DLB) is associated with less temporal lobe atrophy than AD, though posterior cortical atrophy may be greater. Therefore, we assessed whether visual rating scales for assessing posterior atrophy (PA), medial temporal lobe atrophy (MTA), and ventricular enlargement (VEn) aid in the discrimination between AD, DLB, and normal aging.Methods: T1-weighted MRI scans acquired at 3 Tesla were visually rated for PA (range 0–3), MTA (range 0–4), and VEn (range 0–3) in older subjects with AD (n = 36), DLB (n = 35), and healthy controls (n = 35). The diagnostic utility of MTA, PA, and VEn visual ratings in distinguishing AD and DLB from controls as well as AD from DLB was investigated.Results: Significantly higher MTA ratings were associated with AD and DLB compared to controls (p < 0.001). MTA ratings were greater in AD relative to DLB (U = 384.5, p = 0.004). For PA ratings, scores did not differ between groups (p = 0.20). VEn ratings were significantly higher in AD and DLB compared to controls (p = 0.003), but similar between AD and DLB (U = 384.5, p = 0.4).Conclusions: Unlike findings reported in younger subjects, visual ratings for PA are not a reliable marker at older ages for distinguishing AD from controls, or for distinguishing DLB from AD. However, visual ratings of MTA and VEn may be useful markers in distinguishing both AD and DLB from older subjects without dementia.


2020 ◽  
Author(s):  
Jin Ho Jung ◽  
Seun Jeon ◽  
Kyoungwon Baik ◽  
Yang Hyun Lee ◽  
Seok Jong Chung ◽  
...  

Abstract Background: The role of APOE4 in the risk of Alzheimer’s disease, Lewy body disease, and their mixed diseases have not been evaluated in antemortem patients. Also, the APOE4 effect on β-amyloid deposition and cognition, with consideration of both Alzheimer’s and Lewy body diseases, remains unclear. We aimed to determine the APOE4 effects on the risk of Alzheimer’s disease, Lewy body disease, and their mixed diseases, as well as on β-amyloid deposition and cognition after adjusting for the effect of Alzheimer’s disease and Lewy body disease.Methods: Based on clinical features and 18F-Florbetaben and dopamine transporter PET, we recruited 126 controls, 90 patients with typical Alzheimer’s disease (57 pure Alzheimer’s disease, 32 Lewy body variant of Alzheimer’s disease), 77 with typical Lewy body disease (56 pure Lewy body disease, 21 dementia with Lewy bodies with amyloid deposition), and 42 with typical Alzheimer’s disease/dementia with Lewy bodies. We used logistic regression analysis to investigate the effect of APOE4 on the risk of each disease and general linear models to investigate the independent and interaction effects of APOE4, Alzheimer’s disease, and Lewy body disease on β-amyloid deposition and cognition. Results: APOE4 was associated with increased risks of all disease subtypes except pure Lewy body disease. APOE4 was associated with increased frontal β-amyloid burden, typical Alzheimer’s disease was associated with increased β-amyloid burden in all lobar regions, and typical Lewy body disease interacted with APOE4 to increase the occipital β-amyloid burden. The interaction of APOE4 and typical Alzheimer’s disease was associated with more severe memory dysfunction, while that of APOE4 and typical Lewy body disease was associated with poorer Clinical Dementia Rating Sum of Boxes. Conclusions: Our findings suggest that the APOE4 effect on disease risk is dependent on β-amyloid deposition and APOE4 is associated with β-amyloid deposition regardless of the clinical diagnosis; however, APOE4 further interacts with typical Lewy body disease to induce worse general cognition and higher occipital β-amyloid deposition and it interacts with typical Alzheimer’s disease to decrease memory function. This study highlights the possible interaction of β-amyloid and Lewy body pathologies converging in the occipital cortex through the APOE4 effect.


Sign in / Sign up

Export Citation Format

Share Document